Exelixis EBIT/Actif

Que fait Exelixis ? Exelixis Inc. is a biopharmaceutical company specializing in cancer research and drug development. It was founded in 1994 and is headquartered in Alameda, California. The company has successfully launched several medications that have had a positive impact on thousands of patients. Exelixis Inc. was founded by Corey Goodman, George Scangos, and John Walker, who had previously worked at Genentech. The company focuses on developing medications for various types of cancer and has had significant success since its inception. It has brought several products to market, including Cabozantinib, which is used to treat thyroid cancer, kidney cancer, and advanced prostate cancer. Exelixis Inc. continues to research and test new medication candidates in the clinical phase. The company's business model is centered around researching and developing medications that target and inhibit overactive proteins and signaling pathways in cancer cells, thereby slowing their growth. Exelixis Inc. often collaborates with other pharmaceutical companies to share development costs and risks. The company is divided into different divisions to treat specific types of cancer such as kidney cancer, liver cancer, thyroid cancer, and lung cancer. It focuses on developing medications with various active ingredients and inhibitors to effectively treat different types of cancer. A notable milestone for the company was the introduction of Cabozantinib, which was approved by the FDA in 2012 for the treatment of advanced kidney cancer and thyroid cancer. It has since been approved in other countries and has helped thousands of patients. Exelixis Inc. is dedicated to developing more accessible and effective cancer medications and works closely with doctors, researchers, and other pharmaceutical companies to find innovative ways to combat cancer cells. In conclusion, Exelixis Inc. is a leading player in cancer research and drug development, with a track record of successful medications and innovative drug candidates. The company aims to make a significant contribution to improving the health of cancer patients. Exelixis est l'une des entreprises les plus populaires sur Eulerpool.